U.S. Food and Drug Administration's responds to Cell Therapeutics' ( CTIC - Get Report) priority review request for pixantrone as a treatment for non-Hodgkin's lymphoma. Sept. 1
The Oncologic Drug Advisory Committee of the Food and Drug Administration meets to review Genzyme's ( GENZ) Clolar and Vion Pharmaceuticals' ( VION.OB) Onrigin, both as a treatment for acute myeloid leukemia. Sept. 2
The same FDA advisory committee meets to review Allos Therapeutics' ( ALTH) pralatrexate for peripheral T-cell lymphoma.
FDA approval decision date for Endo Pharmaceuticals' ( ENDP - Get Report) Nebido, a long-acting testosterone replacement therapy. Sept. 7
FDA approval decision date for Spectrum Pharmaceuticals' ( SPPI - Get Report) Zevalin, a drug for non-Hodgkin's lymphoma. Sept. 9-10
Robert W. Baird Small Cap Health Care Conference Sept. 9-11
Thomas Weisel Partners Healthcare Conference (Boston) and the Rodman & Renshaw 11th Annual Healthcare Conference (New York City) Sept. 11-15
American Society for Bone and Mineral Research (ASBMR) Sept. 12-15
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Sept. 13-15
American College of Clinical Pharmacology (ACCP) Sept. 14-15
Morgan Stanley Healthcare Unplugged Conference Sept. 16
The 16th Annual NewsMakers in the Biotech Industry, sponsored by BioCentury.
The Arthritis Drugs Advisory Committee of the FDA will review Auxilium Pharmaceutical's ( AUXL) Xiaflex for advanced Dupuytren's disease, a condition in which the tendons of the hand that help move the fingers of the hand become thickened and scarred.
FDA approval decision date for Theravance's ( THRX) antibiotic Telavancin.
European Cancer Organization and European Society for Medical Oncology Multidisciplinary Congress Sept. 21-23
UBS Global Life Science Conference Sept. 24
FDA approval decision date for Eurand Pharmaceuticals' ( EURX) Zenpep, a drug for pancreatic insufficiency.
FDA approval decision date for Allos Therapeutics' Pralatrexate for peripheral T-cell lymphoma.
Dendreon ( DNDN) analyst day Sept. 27-Oct. 1
European Association for the Study of Diabetes (EASD) Important clinical trials with potential data readouts in September: Company: Osiris Therapeutics ( OSIR)
Drug/indication: Prochymal for graft-vs.-host disease Company: Acadia Pharmaceuticals ( ACAD)
Drug/indication: pimavanserin for Parkinson's disease pychosis (PDP) Company: Arena Pharmaceuticals ( ARNA)
Drug/indication: lorcaserin for obesity Company: Chelsea Therapeutics ( CHTP)
Drug/indication: droxidopa for orthostatic hypotension -- Written by Adam Feuerstein in Boston